期刊
CIRCULATION
卷 138, 期 23, 页码 E740-E749出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIR.0000000000000613
关键词
AHA Scientific Statements; advanced cardiac life support; adult; anti-arrhythmia agents; cardiopulmonary resuscitation; heart arrest; tachycardia; ventricular; ventricular fibrillation
资金
- NHLBI NIH HHS [K23 HL128814, R01 HL123980] Funding Source: Medline
Antiarrhythmic medications are commonly administered during and immediately after a ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. However, it is unclear whether these medications improve patient outcomes. This 2018 American Heart Association focused update on advanced cardiovascular life support guidelines summarizes the most recent published evidence for and recommendations on the use of antiarrhythmic drugs during and immediately after shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. This article includes the revised recommendation that providers may consider either amiodarone or lidocaine to treat shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据